慢性肝脏疾病中趋化因子CXCL12α与CXCL12β的检测及其意义  

The assessment and significance of CXCL12α and CXCL12β in chronic liver diseases

作　　者：袁星星[1] 朱东[1] 姚瑶[1] 王文静[1] 卢实春[2] 赵秀英 陈煜[4] 肖汀[5] 段钟平[4] 

机构地区：[1]首都医科大学附属北京佑安医院临床检验中心,100069 [2]首都医科大学附属北京佑安医院肝胆外科,100069 [3]北京清华长庚医院检验科 [4]首都医科大学附属北京佑安医院人工肝中心,100069 [5]中国医学科学院肿瘤医院病因室

出　　处：《北京医学》2014年第3期163-166,共4页Beijing Medical Journal

基　　金：国家自然科学基金(30973388);吴阶平医学基金会肝病实验诊断研究基金(LDWMF-SY-2011A002)

摘　　要：目的：探讨慢性肝脏疾病中趋化因子CXCL12α和CXCL12β水平的变化及其临床意义。方法应用实时定量逆转录PCR检测72例肝癌、72例癌旁、20例肝纤维化及8例正常新鲜肝组织标本CXCL12α、12βmRNA的表达；ELISA检测71例慢性肝炎、24例肝硬化、26例肝癌患者及34例健康体检者血清CXCL12α、β的水平。结果肝癌、癌旁及肝纤维化组织中CXCL12αmRNA表达均高于CXCL12βmRNA，肝癌和癌旁组的差异有统计学意义（P=0.02，P 〈0.001）；肝癌、癌旁、肝纤维化组CXCL12α、12βmRNA水平均高于正常组。慢性肝炎、肝硬化、肝癌及正常组血清 CXCL12α水平分别为（497.44±216.54）、（675.17±565.43）、（812.54±446.69）、（282.47±220.78）pg/ml；CX-CL12β水平为（1619.72±730.22）、（1177.12±541.78）、（2487.96±1192.79）、（281.69±217.08）pg/ml；肝炎、肝硬化、肝癌组血清CXCL12α、12β含量均高于正常对照组。肝硬化及肝癌组血清CXCL12α水平明显高于肝炎组（P 〈0.05）；肝硬化组血清CXCL12β含量低于肝炎和肝癌组（P 〈0.05）。在肝炎患者中，随着肝纤维化程度加重（S1~S4期），血清CX-CL12β含量升高，组间尚无明显差异（P=0.28）；血清CXCL12α水平无显著变化（P =0.686）。结论慢性肝脏疾病进展过程中CXCL12α、12β的表达差异显著，可成为慢性肝病辅助诊断和疾病监测的候选指标。Objective To investigate the change and clinical significance of chemokine CXCL12α and CXCL12βin chronic liver diseases. Methods A total of 72 liver tissues and corresponding adjacent tissue samples of hepatocellular carcinoma （HCC）,20 fibrotic liver tissues and 8 normal controls were tested. One hundred and fifty-five serum samples were also collected, 71 samples were from chronic hepatitis, 24 from cirrhosis, 26 from HCC and 34 from healthy controls. Tissue and serum samples were tested by Real-time RT-PCR and ELISA. Results Real-time RT-PCR results indicated that the mRNA level of CXCL12αwas higher than that of CXCL12βboth in HCC （P =0.02）, adjacent cancer （P 〈0.001） and fibrotic tissues （P = 0.05）. The serum CXCL12α concentration in hepatitis, cirrhosis, HCC group and normal controls were （497.44 ±216.54）, （675.17 ±565.43）, （812.54 ±446.69）, （282.47 ±220.78）pg/ml respectively; followed by the concentration of CXCL12β were（1 619.72±730.22）, （1 177.12±541.78）, （2 487.96±1 192.79）, （281.69±217.08）pg/ml. The expression of CXCL12α, 12β in patients with hepatitis, cirrhosis and HCC were higher than those in healthy controls. Serum CXCL12αin cirrhosis and HCC patients were much higher than those in hepatitis patients （P〈0.05）;CXCL12βin cirrhosis patients were lower than in the hepatitis and HCC patients （P〈0.05）. The content of serum CXCL12βincreased gradually as the degree of hepatic fibrosis aggravating（S1-S4）, yet there were no significant differences between groups （P=0.28）. Meanwhile, the serum CXCL12αhad no statistical change among patients in stage S1-S4 hepatic fibrosis （P =0.686）. Conclusion The expression of CXCL12αand 12βdiffers significantly in chronic liver diseases, which can be a candidate indicator in chronic liver disease diagnosis and monitoring.

关 键 词：CXCL12α CXCL12β 慢性肝炎 肝硬化 肝癌 

分 类 号：R575[医药卫生—消化系统] R735.7[医药卫生—内科学]